[ad_1]
Jakarta, CNBC Indonesia – PT Bio Farma provided clarification on the effectiveness of the Sinovac vaccine, which was said to have reached 97%. Bio Farma Corporate Secretary Bambang Heriyanto said the interim report on the results of the clinical trial is expected to be published in January 2021.
“As of now, the phase 3 clinical trial is still ongoing, and the interim report is estimated to be available in January,” Bambang told CNBC Indonesia on Tuesday (8/12/2020).
It revealed that the results of the clinical trial team report from the Padjadjaran University School of Medicine would be a reference for the Food and Drug Supervision Agency (BPOM) to grant permission for its emergency use.
“Clinical trial data from the Unpad College of Medicine clinical trial team will then be sent directly to BPOM for evaluation for the approval process for emergency use,” he explained.
Previously, the corona vaccine manufactured by Sinovac was said to have a 97% efficacy rate against Covid-19.
“Our clinical trial team found that the data showed an efficacy of up to 97%,” said Iwan Setiawan, spokesman for Bio Farma, as quoted by Reuters, on Tuesday (8/12/2020).
However, on that occasion, Iwan did not specify more clearly where the 97% efficacy result came from.
Previously, Sinovac revealed that its CoronaVac vaccine has a 97% efficacy rate against Covid-19 infection in healthy adults who received lower doses in phase 1 and phase 2 clinical trials.
A Sinovac spokesperson said on Tuesday (8/12/2020) that the biotech company had not received any efficacy results from its third-phase clinical trial. Meanwhile, the Brazilian Institute of Butantan is expected to release data on the final stage of the CoronaVac vaccine clinical trial in Brazil on December 15, 2020.
[Gambas:Video CNBC]
(hps / hps)
